F-1/A: POMDOCTOR Amends IPO Filing, Details Underwriting Terms

POMDOCTOR LIMITED has filed Amendment No. 7 to its F-1 registration statement, primarily to update its underwriting agreement and related offering terms for its upcoming initial public offering of American Depositary Shares.

Summary

• Amendment No. 7 to Form F-1 Registration Statement (File No. 333-285771) was filed on September 26, 2025.
• The primary purpose of this amendment is to file Exhibit 1.1, the Form of Underwriting Agreement, and to amend and restate the exhibit index.
• No changes were made to the prospectus included in Amendment No. 6, which was filed on September 19, 2025.
• POMDOCTOR LIMITED, a Cayman Islands company, is preparing for an initial public offering (IPO) of Class A ordinary shares in the form of American Depositary Shares (ADSs).
• Joseph Stone Capital, LLC is acting as the representative of the underwriters for the offering.
• The underwriting discount is set at 7% of the public offering price of the ADSs.
• The company has granted the underwriters an Over-Allotment Option to purchase up to an additional number of ADSs, exercisable within 45 days after the closing of the offering.
• An escrow agreement will be established, requiring $200,000 from the offering proceeds to be deposited into an escrow account for indemnification purposes, with remaining funds to be returned after 12 months if not subject to claims.
• The company will reimburse the representative for certain accountable expenses, capped at $200,000 for specific items, and pay a non-accountable expense allowance of 1.0% of the proceeds (excluding Over-Allotment Option shares).
• An advisory fee of $40,000 will be paid to the representative at closing.
• The company and its officers, directors, and certain shareholders will be subject to lock-up agreements, restricting the sale of securities for 12 months (company) and 6 months (insiders) after the closing date.
• The securities have been approved for listing on the Nasdaq Global Market, subject to official notice of issuance.
• The company has completed filing requirements under the CSRC Filing Rules in connection with this offering.

Sentiment

Score: 7

Explanation: The filing indicates steady and expected progress towards an IPO, with key agreements and regulatory compliance steps being addressed. While the IPO process itself can be lengthy (evidenced by Amendment No. 7 and delaying amendment), the approval for Nasdaq listing and the detailed underwriting terms suggest a clear path forward. The costs associated with the offering are standard for an IPO of this nature. No negative surprises, but also no immediate catalysts for significant positive re-evaluation.

Positives

• Progress towards an Initial Public Offering (IPO) is evident with the filing of an updated underwriting agreement and exhibit index.
• The company's securities have been approved for listing on the Nasdaq Global Market, subject to official notice of issuance, indicating a significant step towards public trading.
• POMDOCTOR has secured directors and officers liability insurance and public offering securities insurance, providing protection for management and the offering.
• The company has complied with the CSRC Filing Rules for overseas securities offerings, addressing a key regulatory hurdle for PRC-related entities.

Negatives

• The underwriting discount of 7% of the public offering price, coupled with a 1.0% non-accountable expense allowance and a $40,000 advisory fee, represents a substantial cost of capital for the company.
• The SEC's opinion that indemnification for liabilities arising under the Securities Act is against public policy could potentially leave directors and officers exposed to certain legal risks, despite the company's indemnification provisions.
• The filing is Amendment No. 7, suggesting a prolonged IPO process since the initial F-1 filing, which could imply complexities or delays in bringing the offering to market.

Risks

• Indemnification for liabilities arising under the Securities Act may be deemed unenforceable by the SEC, potentially increasing personal liability for directors and officers.
• The underwriting agreement can be terminated if a Material Adverse Change occurs prior to closing, including significant changes in financial markets or outbreaks of hostilities, which could prevent the offering from being completed.
• Underwriter default risk exists, where if defaulting underwriters exceed 10% of the offering, the agreement may terminate, though provisions allow for non-defaulting underwriters to cover smaller defaults.
• The company's ability to comply with all applicable PRC Overseas Investment and Listing Regulations is ongoing and critical, and non-compliance could lead to regulatory issues.
• The company does not believe it was a Passive Foreign Investment Company (PFIC) for its most recent taxable year and does not expect to become one for its current taxable year, but this status is subject to change based on income and assets.

Future Outlook

The company intends to apply the net proceeds from the sale of American Depositary Shares for the purposes outlined in the prospectus. It will file all required reports with the SEC regarding the sale and application of proceeds. The company expects to maintain its status as an Emerging Growth Company and a Foreign Private Issuer. The securities have received approval for listing on the Nasdaq Global Market, subject to official notice of issuance, indicating an anticipated public trading debut.

Management Comments

• The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant files a further amendment which specifically states that this Registration Statement will thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement becomes effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
• The Company will promptly notify the Underwriters if the Company ceases to be an Emerging Growth Company at any time prior to the later of (i) completion of the distribution of Securities within the meaning of the Securities Act and (B) completion of the 180-day restricted period referenced to in Section 4(n) hereof.
• The Company does not believe it was a Passive Foreign Investment Company (PFIC) within the meaning of Section 1297 of the United States Internal Revenue Code of 1986, as amended, for its most recent taxable year, and does not expect to become a PFIC for its current taxable year.

Industry Context

This filing is a standard procedural step for a company, POMDOCTOR LIMITED, to go public in the U.S. market. As a "Foreign Private Issuer" from the Cayman Islands with operations likely in the PRC (indicated by addresses and counsel), it navigates specific regulatory frameworks like the CSRC Filing Rules. The mention of "Qilekang Digital Health" as a Consolidated Affiliated Entity suggests the company operates within the digital health or health technology sector, an industry experiencing significant growth and innovation globally. The engagement of a U.S. underwriter and plans for Nasdaq listing indicate an ambition to tap into international capital markets and gain global visibility, a common trend for emerging companies in high-growth sectors.

Comparison to Industry Standards

• The underwriting discount of 7% is typical for smaller-cap IPOs, often ranging from 5% to 7% for offerings under $100 million, aligning with industry norms for emerging companies.
• The 12-month lock-up period for the company and 6-month lock-up for officers, directors, and significant shareholders are standard practice in IPOs to ensure market stability post-offering and align insider interests with long-term performance.
• The establishment of a $200,000 escrow account for indemnification is a common protective measure for underwriters, similar to arrangements seen in other IPOs to cover potential legal liabilities.
• The cap on accountable expenses for the underwriter ($200,000) is a standard provision to manage offering costs, comparable to agreements in other small to mid-cap IPOs.
• The company's compliance with CSRC Filing Rules is a critical and increasingly common requirement for PRC-based companies seeking overseas listings, reflecting evolving regulatory landscapes.

Corporate Governance

Related Party Transactions

• An advertising service agreement was entered into with Focus Media, Inc. (an indirectly wholly-owned subsidiary of Focus Media Information Technology Co., Ltd.) from February 29, 2020, to February 28, 2021, with RMB221.0 million payable as of December 31, 2020.
• On August 10, 2021, these payables were transferred to Aixiangbao on the condition that Focus Media, Inc. or its designated party obtained a 9.82% equity interest in the VIE.
• Subsequently, 1,958,119 Series B-4 preferred shares were issued to Nova Compass Investment Limited, which is controlled by Focus Media Information Technology Co., Ltd., on August 18, 2021.

Stakeholder Impact

• Shareholders: Existing shareholders will experience dilution from the issuance of new shares in the IPO. Officers, directors, and beneficial owners of 10% or more of outstanding shares will be subject to lock-up agreements, restricting sales for 6 months, while the company itself has a 12-month lock-up. New public shareholders will gain liquidity through Nasdaq listing.
• Directors and Officers: Will benefit from indemnification provisions in the company's articles of association and separate indemnification agreements, although the SEC's stance on enforceability for Securities Act liabilities presents a potential risk. They are also subject to 6-month lock-up agreements.
• Underwriters (Joseph Stone Capital, LLC): Will receive a 7% underwriting discount, a 1.0% non-accountable expense allowance, and a $40,000 advisory fee, along with indemnification protection.
• Employees: The 2025 Share Incentive Plan is mentioned as an exhibit, suggesting potential future equity compensation opportunities.

Next Steps

• The company needs to finalize the effective date of the registration statement.
• The proposed sale of securities to the public will commence as soon as practicable after the effective date.
• The underwriters may exercise the Over-Allotment Option within 45 days after the closing of the offering.
• The company will file periodic and special reports with the Commission as required by the Exchange Act.
• The company will make generally available an earnings statement covering a 12-month period beginning after the effective date of the Registration Statement, as required by Rule 158.
• The company will maintain a registrar and transfer agent and retain a public relations firm for at least one year from the First Closing Date.
• The company will continue to comply with PRC Overseas Investment and Listing Regulations.

Key Dates

Recommendation

This filing is a procedural amendment to an F-1 registration statement, primarily updating the underwriting agreement and exhibit index for an upcoming IPO. It does not contain new financial performance data or operational updates that would fundamentally alter the company's intrinsic value or immediate prospects. While the progress towards listing on Nasdaq is positive, the actual pricing and market reception of the IPO are yet to be determined. Therefore, a "hold" recommendation is appropriate for existing investors, advising them to maintain their current position and await further developments, particularly the final IPO terms and initial trading performance. For potential investors, this filing provides necessary background but not a definitive signal for immediate action.

Keywords

IPO, F-1/A, SEC Filing, Underwriting Agreement, American Depositary Shares, ADSs, Nasdaq, Joseph Stone Capital, POMDOCTOR LIMITED, Cayman Islands, China, Emerging Growth Company, Foreign Private Issuer, Lock-Up, Indemnification, Capital Raise, CSRC Filing Rules, Digital Health